Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sagimet Biosciences Inc.

Get SEC filing alerts via email and in your feed for Sagimet Biosciences Inc.

SGMT

Sagimet Biosciences Inc.

About Sagimet Biosciences Inc.

Sagimet Biosciences is a biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors to treat metabolic liver diseases like MASH, acne, and certain cancers. Its lead candidate, denifanstat, is an oral pill targeting liver fat, inflammation, and fibrosis. The company focuses on precision medicine, biomarker-driven development, and strategic collaborations to address unmet medical needs in hepatology and oncology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Sagimet Biosciences Inc.

1
1
Sagimet Biosciences Inc. Sagimet Biosciences Reports Q1 2026 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Sagimet Biosciences Inc. Sagimet Biosciences Reports $51M Net Loss for 2025, Increases R&D and G&A Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Sagimet Biosciences Inc. Sagimet Biosciences Reports Q3 2025 Financial Results with $12.9M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Sagimet Biosciences Inc. Sagimet Biosciences Reports $10.4 Million Net Loss in Q2 2025, Driven by Rising Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Sagimet Biosciences Inc. Sagimet Biosciences Reports $18.2 Million Net Loss and Advances Clinical Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Sagimet Biosciences Inc. Sagimet Biosciences Reports $45.6 Million Net Loss and Advances Denifanstat in Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Sagimet Biosciences Inc. Sagimet Biosciences Reports Increased Assets, Wider Losses in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments